Healthcare >> CEO Interviews >> October 1, 2001
ELIZABETH M. GREETHAM, Chairman and CEO of DrugAbuse Sciences, Inc.,
joined the company in 1998 as a member of the Board of Directors. In
April 1999, Ms. Greetham assumed the position of Chief Financial Officer
and Senior Vice President, Business Development. In August 2000, she was
promoted to Chief Executive Officer and in May 2002 was appointed as
Chairman of the Board of Directors. Ms. Greetham is widely known for her
healthcare experience as a sell side analyst, Portfolio Manager and
Board member of several biotechnology companies. Prior to joining DAS,
Ms. Greetham worked for nearly 10 years as a Portfolio Manager for
Weiss, Peck & Greer, an institutional investment management firm. She
managed the WPG Life Sciences Funds, L.P., which invested in select
biotechnology stocks. Prior to that, Ms. Greetham was a consultant to F.
Eberstadt & Co. She has over 30 years of healthcare investment
experience in the United States and Europe. She is a member of the Board
of Directors of Guilford Pharmaceuticals and Stressgen Biotechnologies.
Ms. Greetham earned an MA (Hons.) from the University of Edinburgh,
Scotland. Profile
Sciences, Inc., and an overview of what the company is doing now?
Ms. Greetham: The company was founded in 1994 with the
